OCUPHIRE PHARMA INC. - COMMON STOCK

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

06 Jun 2024 07:57:22 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

10 May 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at the Aegis Virtual Conference

03 May 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

22 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

11 Apr 2024 10:03:48 By Nasdaq GlobeNewswire

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

01 Apr 2024 07:14:52 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

08 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

23 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Feb 2024 16:10:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

14 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 Jan 2024 16:10:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

04 Jan 2024 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

30 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27 Nov 2023 16:38:14 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

27 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

13 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2023 16:52:46 By Nasdaq GlobeNewswire